Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvia officinalis leaf extract is a freeze-dried botanical extract derived from the leaves of the sage plant (*Salvia officinalis*). Developed by the Italian company ABOCA, it is being investigated as a natural phytocomplex therapeutic for the management of postoperative pain, often in combination with *Helichrysum italicum* extract. The extract contains a complex mixture of phytochemicals, including rosmarinic acid, flavonoids, and terpenoids, which exhibit anti-inflammatory and analgesic properties. Its mechanism of action likely involves the modulation of inflammatory mediators such as prostaglandins, cytokines, and cyclooxygenase (COX) enzymes. It has been evaluated in Phase 2 clinical trials for its efficacy in reducing pain following surgical procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salvia officinalis leaf extract.